Interim Results

RNS Number : 4547K
ReNeuron Group plc
14 December 2018
 

 Details are given below of an analyst meeting and webcast at 9.30am this morning

 

 

 

14 December 2018

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or "the Company")

 

 Interim Results for the six months ended 30 September 2018

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2018.

 

Highlights

 

·       CTX stem cell therapy candidate for stroke disability:  

-     Patient screening and enrolment commenced in Phase IIb clinical trial in the US

-     Top line data from Phase IIb study expected in early 2020

 

·       hRPC stem cell therapy candidate for retinal diseases:

-     Optimised formulation of the hRPC drug product developed and approved for use in ongoing Phase I/II clinical trial in retinitis pigmentosa in the US

-     Patient dosing recommenced in Phase I/II study using optimised hRPC formulation

-     Top line data from Phase I/II study expected in mid-2019

 

·       Exosome platform:

-     Programme to be re-focused on use of ExoPr0 as a drug delivery vehicle, providing greater scope for potential near-term partnering deals

 

·       Increased business development activity in the period reflecting third party interest in the Company's core therapeutic programmes

-     Active and well-progressed discussions ongoing with commercial third parties

 

·       Reduced loss for the period of £5.32million (2017: loss of £9.57 million); reduced cash consumed by operations of £7.54 million (2017: £9.22 million); cash, cash equivalents and bank deposits at 30 September 2018 of £30.67 million (31 March 2018: £37.41 million)

 

 

Commenting on the results, Olav Hellebø, Chief Executive Officer, said:

 

"Our therapeutic development programmes have continued to progress well during the period. We are particularly excited to have opened the placebo-controlled Phase IIb clinical trial in the US for CTX in chronic stroke disability.   We remain encouraged by the progress made in partnering discussions across all of our technologies and programmes and we hope to be able to conclude an initial out-licensing agreement in the near term.

 

"We have continued to maintain tight control over our operating costs, reflected in the financial statements for the period.  Our cash position remains robust and we are positioned to deliver significant clinical milestones in our stroke and retinitis pigmentosa programmes over the next 18 months."

 

 

Analyst meeting and webcast:

 

A meeting for analysts will be held at 9.30am today at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.

 

For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.30am:

 

http://webcasting.buchanan.uk.com/broadcast/5bf3e08d1a82c37e3088a28b

 

For further details please contact Buchanan on 020 7466 5000 or email .

 

A recording of the webcast will be made available on ReNeuron's website, www.reneuron.com.

 

Enquiries:

 

+44 (0) 20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan

 

+44 (0) 20 7466 5000




Stifel Nicolaus Europe Limited

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

+44 (0) 20 7710 7600

N+1 Singer

Mark Taylor / Aubrey Powell (Joint Broker)

 

+44 (0) 20 7496 3000

 

This announcement contains inside information. The person responsible for arranging for the release of this announcement on behalf of the Company is Olav Hellebø, Chief Executive Officer.

 

About ReNeuron

 

ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

 

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   

 

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking also statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

 

Review of therapeutic programmes

 

CTX for stroke disability

 

During the period under review, we have progressed our CTX cell therapy candidate for stroke disability into a Phase IIb clinical trial in the US.  The study, PISCES III, is a placebo-controlled clinical trial and will involve 110 patients across 40 clinical trial sites in the US. 

 

Patients in the study will be treated between 6 and 12 months after their stroke and will be randomised to receive either the CTX therapy or placebo treatment.  The primary end-point of the PISCES III study is the proportion of patients in the treated and placebo arms showing a clinically important improvement on the modified Rankin Scale (mRS) at six months post-treatment compared with baseline.  The mRS is a global measure of disability or dependence upon others in carrying out activities of daily living and is accepted by regulatory authorities as an appropriate end-point for marketing approval in stroke disability.

 

To date, 33 out of the 40 sites targeted for participation in the PISCES III study have been identified and the first sites have now been opened, with patient screening and recruitment underway. We expect the first patient in the study to be randomised shortly and, subject to meeting patient recruitment targets, we expect top-line data from the study in early 2020.  We expect the PISCES III clinical trial to be one of two pivotal studies required to support a marketing authorisation for the therapy in this indication.

 

 

During the period, we successfully developed a new cryo-preserved formulation of the hRPC drug product to optimise the sub-retinal implantation of the cells and to extend the shelf life of the drug product.  Following the requisite regulatory approvals for this new hRPC formulation, we have recommenced patient dosing in the ongoing Phase I/II study in the US in retinitis pigmentosa (RP).  evaluate the safety, tolerability and preliminary efficacy of our hRPC stem cell therapy candidate in patients with advanced RP.

 

The clinical trial protocol for the Phase I/II study has been amended to allow for a larger patient population to be treated in the study and for a further study centre to be added, which will be open for patient enrolment shortly.  Based on this, we expect short term read-outs from the Phase I/II study in mid-2019, with a Phase IIb study planned to commence thereafter.  As also reported previously, we intend to seek approval to commence a Phase II clinical trial with our hRPC cell therapy candidate in patients with cone-rod dystrophy (CRD) to begin shortly after the start of Phase IIb testing of this candidate in RP.  CRD is a group of rare eye disorders associated with a loss of cone cells in the retina resulting in deterioration of central visual acuity and colour vision. 

 

Exosome platform

 

Pre-clinical development work has continued during the period with ExoPr0, our first CTX-derived exosome therapeutic candidateExosomes are nanoparticles secreted from cells including our proprietary CTX stem cell line.  Exosomes play a key role in cell-to-cell signalling and early research with ExoPr0 has demonstrated its potential as both a novel therapeutic candidate and as a drug delivery vehicle.  

 

We have recently reassessed how best to exploit our CTX cell-based exosome platform to maximise potential near-term commercial opportunities.  In this regard, we intend to devote greater resource to the application of ExoPr0 as a vector for delivering biological drugs since this is where we see the greatest near-term opportunity for value-generating business development deals.  We will therefore devote less internal resource to the pursuit of ExoPr0 as a therapeutic agent in its own right, preferring instead to pursue this application in collaboration with other academic and commercial third parties under existing grant-funded programmes.  As a result, we do not now expect to undertake the previously planned oncology clinical trial with ExoPr0 in 2019.

Other activities

 

During October, we presented data demonstrating for the first time that our lead CTX cell line can be successfully reprogrammed to an embryonic stem cell-like state and then differentiated along a different path from the original cell line.  Importantly, ReNeuron's immortalisation technology remained functional in the reprogrammed cells.  These results, albeit early stage, are particularly encouraging as they demonstrate that our CTX cell line could be used to produce new conditionally immortalised allogeneic (i.e. non-donor-specific) cell lines from any of the three germ layers: ectoderm, mesoderm and endoderm. We are now working to develop further new allogeneic cell lines, including NK and T-cells (the cells that can be modified to attack cancer cells), as potential therapeutic agents for out-licensing to third parties.

 

Our technologies and therapeutic programmes have increasingly attracted the interest of commercial third parties as they have progressed through pre-clinical and clinical development.  As a result, we are in active and well-progressed discussions with commercial third parties relating to all of our platform technologies and programmes, with a view to potential collaboration and/or out-licensing deals in due course.  These potential deals, if successfully concluded, will provide strong third-party validation to our technologies and programmes as well as an important source of potential non-dilutive funding to the Company.

 

During the period, an exclusivity fee of $2.5 million was received from one such third party relating to a potential out-license of our hRPC retinal stem cell technology. Although this particular potential licensee withdrew from the deal for reasons unrelated to ReNeuron's technology, we remain confident of securing an initial out-licence deal in the near term.    

 

 

In the six months to 30 September 2018, revenues were £27,000 (2017: £24,000) in addition to which grant income of £508,000 was received and is shown as other operating income (2017: £240,000). Other operating income also includes £1,893,000 (2017: £Nil) in respect of the exclusivity fee received during out-licencing negotiations.

 

Total operating costs reduced in the period to £10.10 million (2017: £10.81 million). Research and development expenditure reduced to £7.54 million (2017: £8.60 million). The higher cost in the prior period reflects heightened manufacturing process development activity ahead of the commencement of the ongoing clinical trials in stroke disability and retinitis pigmentosa. General and administrative expenses increased to £2.56 million (2017: £2.21 million) as a result of increased costs associated with higher levels of business development activity. 

 

Finance income represents income received from the Group's cash and investments and gains from foreign exchange, with losses from foreign exchange shown in finance expense.  Finance income was £0.89 million in the period (2017: £0.19 million) including foreign exchange gains of £0.75 million.  In 2017, the movement in foreign exchange rates led to a foreign exchange loss of £0.62 million. The Group holds cash and investments in foreign currencies in order to hedge against operational spend in those currencies.  The strengthening of sterling against the US dollar during the period has resulted in a relative appreciation of the Group's foreign currency deposits.  The total tax credit for the period was £1.46 million (2017: £1.40 million).

 

As a result of the above, the total comprehensive loss for the period reduced to £5.32 million (2017: £9.57 million).

 

Cash consumed by operations in the period reduced to £7.54 million (2017: £9.22 million), broadly reflecting the receipt of the £1.9m exclusivity fee in the period and lower operating costs, offset by a reduction in working capital compared with the prior period.  The Group had cash, cash equivalents and bank deposits totalling £30.67 million as at 30 September 2018 (31 March 2018: £37.41 million).

 

Summary and outlook

 

Our therapeutic development programmes have continued to progress well during the period. We are particularly excited to have opened the placebo-controlled Phase IIb clinical trial in the US for CTX in chronic stroke disability. We remain encouraged by the progress made in partnering discussions across all of our technologies and programmes and we hope to be able to conclude an initial out-licensing agreement in the near term.

 

We have continued to maintain tight control over our operating costs, reflected in the financial statements for the period. Our cash position remains robust and we are positioned to deliver significant clinical milestones in our stroke and retinitis pigmentosa programmes over the next 18 months.

 

Hellebø

Chief Executive Officer

 

14 December 2018

 

 

Unaudited Consolidated Statement of Comprehensive Income

for the six months ended 30 September 2018

 



Six months ended

Six months ended

Year ended



 30 September

 30 September

 31 March



2018

2017

2018


Note

£'000

£'000

£'000

Revenue


27

24

43

Research and development costs


(7,543)

(8,599)

(16,657)

General and administrative costs


(2,560)

(2,210)

(4,616)

Other operating income

5

2,401

240

854

Operating loss


(7,675)

(10,545)

(20,376)

Finance income

6

893

188

320

Finance expense

7

-

(616)

(911)

Loss before income taxes


(6,782)

(10,973)

(20,967)

Tax credit on loss on ordinary activities


1,457

1,404

3,352

Total comprehensive loss for the period


(5,325)

(9,569)

(17,615)

Total comprehensive loss attributable to:





   - Equity owners of the Company


(5,325)

(9,569)

(17,615)






Basic and diluted loss per share

8

(16.8p)

(30.2p)

(55.7p)

 

 

Unaudited Consolidated Statement of Financial Position

as at 30 September 2018

 



30 September

30 September

31 March



2018

2017

2018



£'000

£'000

£'000

Assets





Non-current assets





Property, plant and equipment


727

685

726

Intangible assets


186

186

186



913

871

912

Current assets





Trade and other receivables


1,057

812

1,285

Corporation tax receivable


4,467

3,529

3,010

Investments - bank deposit


5,951

23,923

9,500

Cash and cash equivalents


24,722

21,359

27,911



36,197

49,623

41,706

Total assets


37,110

50,494

42,618






Equity





Equity attributable to owners of the Company





Share capital


316

31,646

316

Share premium


97,704

97,704

97,704

Capital redemption reserve


40,294

8,964

40,294

Merger reserve


2,223

2,223

2,223

Accumulated losses


(108,629)

(96,381)

(103,868)

Total equity


31,908

44,156

36,669

Liabilities





Current Liabilities





Trade and other payables


5,202

6,338

5,949

Total liabilities


5,202

6,338

5,949

Total equity and liabilities


37,110

50,494

42,618






 

 

Unaudited Consolidated Statement of Changes in Equity

for the six months ended 30 September 2018

 










Share

Capital





Share

premium

Redemption

Merger

Accumulated losses

Total


capital

account

Reserve

reserve


Equity


£'000

£'000

£'000

£'000

£'000

£'000

As at 1 April 2017

31,646

97,704

8,964

2,223

(87,380)

53,157








Share-based credit

-

-

-

-

568

568








Loss for the period

-

-

-

-

(9,569)

(9,569)








As at 30 September 2017

31,646

97,704

8,964

2,223

(96,381)

44,156








Effect of share consolidation

(31,330)

-

31,330

-

-

-








Share-based credit

-

-

-

-

559

559








Loss for the period

-

-

-

-

(8,046)

(8,046)








As at 31 March 2018

316

97,704

40,294

2,223

(103,868)

36,669








Share-based credit

-

-

-

-

564

564








Loss for the period

-

-

-

-

(5,325)

(5,325)








As at 30 September 2018

316

97,704

40,294

2,223

(108,629)

31,908

 

 

Unaudited Consolidated Statement of Cash Flows

for the six months ended 30 September 2018

 



Six months ended

Six months ended

Year ended



30 September

30 September

 31 March



2018

2017

2018


Note

£'000

£'000

£'000

Cash consumed by operations

9

(7,541)

(9,221)

(19,244)






Income tax credit received


-

1,890

4,357

Cash outflow from operating activities


(7,541)

(7,331)

(14,887)






Cash flows from investing activities





Capital expenditure


(133)

(72)

(235)

Interest received


188

240

383

Net cash generated by investing activities


55

168

148






Cash flows from financing activities





Bank deposit matured


4,297

397

14,525

Net cash generated by financing activities


4,297

397

14,525






Net decrease in cash and cash equivalents


(3,189)

(6,766)

(214)

Cash and cash equivalents at the start of period


27,911

28,125

28,125

Cash and cash equivalents at the end of period


24,722

21,359

27,911

 

 

Notes to the interim financial statements

for the six months ended 30 September 2018

 

1.               General information and basis of preparation

 

ReNeuron Group plc is an AIM listed company incorporated and domiciled in the United Kingdom under the Companies Act 2006. The Company's registered office and its principal place of business is Pencoed Business Park, Pencoed, Bridgend, CF35 5HY.

 

These Interim Financial Statements were prepared by the Directors and approved for issue on 14 December 2018. They have not been audited.

 

These Interim Financial Statements do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 March 2018 were approved by the Board of Directors on 19 July 2018 and delivered to the Registrar of Companies. The report of the auditors on those accounts was unqualified and did not contain statements under 498 (2) or (3) of the Companies Act 2006 and did not contain any emphasis of matter.

 

As permitted these Interim Financial Statements have been prepared in accordance with UK AIM rules and the IAS 34, 'Interim financial reporting' as adopted by the European Union. They should be read in conjunction with the Annual Financial Statements for the year ended 31 March 2018, which have been prepared in accordance with IFRS as adopted by the European Union.

 

2.               Accounting policies

 

The accounting policies applied are consistent with those of the Annual Financial Statements for the year ended 31 March 2018, as described in those Annual Financial Statements. Where new standards or amendments to existing standards have become effective during the year, there has been no material impact on the net assets or results of the Group.

 

Certain statements within this report are forward looking. The expectations reflected in these statements are considered reasonable. However, no assurance can be given that they are correct. As these statements involve risks and uncertainties the actual results may differ materially from those expressed or implied by these statements.

 

3.               Going concern

 

The Group is expected to incur significant further costs as it continues to develop its therapies and technologies through clinical development.  The operation of the Group is currently being financed from funds that have been raised from share placings and grants.

 

The Directors expect that the Group's current financial resources will be sufficient to support operations for at least the next 12 months from the date of this report. The Directors are currently considering a number of options for further funding and believe that sufficient funding will be available beyond current cash resources in order to continue with the Group's ongoing clinical programmes. Consequently, the going concern basis has been adopted in the preparation of these interim financial statements.

 

 

4.               Segment information

 

The Group has identified the Chief Executive Officer as the chief operating decision maker (CODM). The CODM manages the business as one segment, the development of cell-based therapies, and assets are predominantly based in the UK. Since this is the only reporting segment, no further information is included. The information used internally by the CODM is the same as that disclosed in the interim financial statements. The Group's revenue derives wholly from assets located in the United Kingdom. Analysed by location of customer all revenue is derived from the United States of America.

 

5.               Other operating income

 


Six months ended

Six months ended

Year ended


30 September

30 September

 31 March


2018

2017

2018


£'000

£'000

£'000





Government grants

508

240

854

Exclusivity fee

1,893

-

-


2,401

240

854

 

6.               Finance income

 


Six months ended

Six months ended

Year ended


30 September

30 September

 31 March


2018

2017

2018


£'000

£'000

£'000





Interest received

146

188

320

Foreign exchange gains

747

-

-


893

188

320

 

7.               Finance expense

 


Six months ended

Six months ended

Year ended


30 September

30 September

 31 March


2018

2017

2018


£'000

£'000

£'000





Foreign exchange losses

-

616

911





 

 

8.               Basic and diluted loss per share

 

The basic and diluted loss per share is calculated by dividing the loss for the financial period of £5,325,000 (September 2017: £9,569,000, March 2018: £17,615,000) by 31,646,186 shares (September 2017 and March 2018: 31,646,186 shares), being the weighted average number of ordinary 1p shares in issue during the period. Potential ordinary shares are not treated as dilutive as the entity is loss-making. The comparative figure for September 2017 has been adjusted to reflect the 1 for 100 share consolidation which took place in January 2018.

 

9.               Cash consumed by operations

 


Six months ended

Six months ended

Year ended


30 September

30 September

 31 March


2018

2017

2018


£'000

£'000

£'000

Loss before income tax

(6,782)

(10,973)

(20,967)

Adjustment for:




Finance income

(893)

(188)

(320)

Depreciation of tangible fixed assets

137

110

232

Share-based payment charge

564

568

1,127

Finance expense

-

616

911





Changes in working capital




Receivables

186

196

(289)

Payables

(753)

450

62

Cash consumed by operations

(7,541)

(9,221)

(19,244)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IR FFAFWDFASEDE
UK 100

Latest directors dealings